Bristol-Myers Squibb and Otsuka Stabilize Their Bases
Executive Summary
The related deals between Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. announced in April appear to be a win for both sides. They extend and update a highly successful 10-year-old collaboration, essentially tweaking the original agreement's terms in consideration of each partner's current needs. At the same time, they recognize that the key product involved, the antipsychotic medication Abilify, is reaching maturity.
You may also be interested in...
With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
Four years ago, Bristol management changed course and established the company as a pure play biopharma. Now, with the launch of Yervoy for metastatic melanoma and a late-stage pipeline that is chock-full, the strategy appears about to pay off. CEO Lamberto Andreotti and R&D president Elliott Sigal talked with IN VIVO about the launch of Yervoy and how Bristol, relying on R&D productivity, not diversification, is on track to overcome the extensive patent losses ahead.
With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
Four years ago, Bristol management changed course and established the company as a pure play biopharma. Now, with the launch of Yervoy for metastatic melanoma and a late-stage pipeline that is chock-full, the strategy appears about to pay off. CEO Lamberto Andreotti and R&D president Elliott Sigal talked with IN VIVO about the launch of Yervoy and how Bristol, relying on R&D productivity, not diversification, is on track to overcome the extensive patent losses ahead.
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Sanofi-Aventis' much publicized pursuit - first hostile, then friendly - of Genzyme dominated biopharma news flow for more than half a year, with well timed information leaks and dramatic "he said, he said" commentary from the firms' CEOs. Such back and forth ensured continued high profile coverage until the companies officially affianced. But beyond the drama, the $20.1 billion deal, among the largest since the 2009 mega-mergers between Pfizer and Wyeth and Merck & Co. and Schering-Plough Corp., is worth discussion because it provides insight into what now drives big pharma dealmaking in the post-blockbuster era - and how companies want to pay for it.